Hong Kong Exchange’s biotech recruitment drive creates potential bridge between traditional IPO infrastructure and tokenized healthcare assets. The December Insilico Medicine launch demonstrates institutional appetite for science-backed offerings that could eventually integrate with decentralized finance protocols.
Source: FinanceAsia Read Full Story